Donate Help Contact The AHA Sign In Home
American Heart Association
Circulation
Search: search_blue_button Advanced Search
Circulation. 2008;117:1778-1786
Published online before print March 31, 2008, doi: 10.1161/CIRCULATIONAHA.107.731893
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
117/14/1778    most recent
CIRCULATIONAHA.107.731893v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Gellen, B.
Right arrow Articles by Mercadier, J.-J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Gellen, B.
Right arrow Articles by Mercadier, J.-J.
Right arrowPubmed/NCBI databases
*Compound via MeSH
*Substance via MeSH
Hazardous Substances DB
*DOXYCYCLINE
Related Collections
Right arrow Arrythmias-basic studies
Right arrowRelated Article

(Circulation. 2008;117:1778-1786.)
© 2008 American Heart Association, Inc.


Arrhythmia/Electrophysiology

Conditional FKBP12.6 Overexpression in Mouse Cardiac Myocytes Prevents Triggered Ventricular Tachycardia Through Specific Alterations in Excitation- Contraction Coupling

Barnabas Gellen, MD; María Fernández-Velasco, PhD*; François Briec, MD*; Laurent Vinet, MS*; Khai LeQuang, MD; Patricia Rouet-Benzineb, PhD; Jean-Pierre Bénitah, PhD; Mylène Pezet, PhD; Gael Palais, MS; Noémie Pellegrin, MS; Andy Zhang, MS; Romain Perrier, MS; Brigitte Escoubet, MD, PhD; Xavier Marniquet, MS; Sylvain Richard, PhD; Fréderic Jaisser, MD, PhD; Ana María Gómez, PhD; Flavien Charpentier, PhD; Jean-Jacques Mercadier, MD, PhD

From Inserm, U698, Paris (B.G., L.V., P.R.-B., N.P., X.M., J.-J.M.); Inserm, U637, Montpellier (A.M.G., J.-P.B., M.F.-V., R.P., S.R.); Inserm, U915, Nantes (K.L., F.B., F.C.); Inserm, U772, Paris (G.P., A.Z., B.E., F.J.); CEFI-IFR02, Paris (M.P., B.E., J.-J.M.); and Université Paris Diderot and Assistance Publique–Hôpitaux de Paris, Paris (B.E., J-.J.M.), France.

Correspondence to Dr Jean-Jacques Mercadier, Inserm, U698, G.H. Bichat–Claude Bernard, 46 Rue Henri Huchard, 75018 Paris, France. E-mail mercadie{at}bichat.inserm.fr

Received March 22, 2007; accepted February 7, 2008.

Background— Ca2+ release from the sarcoplasmic reticulum via the ryanodine receptor (RyR2) activates cardiac myocyte contraction. An important regulator of RyR2 function is FKBP12.6, which stabilizes RyR2 in the closed state during diastole. β-Adrenergic stimulation has been suggested to dissociate FKBP12.6 from RyR2, leading to diastolic sarcoplasmic reticulum Ca2+ leakage and ventricular tachycardia (VT). We tested the hypothesis that FKBP12.6 overexpression in cardiac myocytes can reduce susceptibility to VT in stress conditions.

Methods and Results— We developed a mouse model with conditional cardiac-specific overexpression of FKBP12.6. Transgenic mouse hearts showed a marked increase in FKBP12.6 binding to RyR2 compared with controls both at baseline and on isoproterenol stimulation (0.2 mg/kg IP). After pretreatment with isoproterenol, burst pacing induced VT in 10 of 23 control mice but in only 1 of 14 transgenic mice (P<0.05). In isolated transgenic myocytes, Ca2+ spark frequency was reduced by 50% (P<0.01), a reduction that persisted under isoproterenol stimulation, whereas the sarcoplasmic reticulum Ca2+ load remained unchanged. In parallel, peak ICa,L density decreased by 15% (P<0.01), and the Ca2+ transient peak amplitude decreased by 30% (P<0.001). A 33.5% prolongation of the caffeine-evoked Ca2+ transient decay was associated with an 18% reduction in the Na+-Ca2+ exchanger protein level (P<0.05).

Conclusions— Increased FKBP12.6 binding to RyR2 prevents triggered VT in normal hearts in stress conditions, probably by reducing diastolic sarcoplasmic reticulum Ca2+ leak. This indicates that the FKBP12.6-RyR2 complex is an important candidate target for pharmacological prevention of VT.


 

CLINICAL PERSPECTIVE


Related Article:

Clinical Summaries
Circulation 2008 117: 1769. [Extract] [Full Text]



This article has been cited by other articles:


Home page
CirculationHome page
A. M. Gomez, A. Rueda, Y. Sainte-Marie, L. Pereira, S. Zissimopoulos, X. Zhu, R. Schaub, E. Perrier, R. Perrier, C. Latouche, et al.
Mineralocorticoid Modulation of Cardiac Ryanodine Receptor Activity Is Associated With Downregulation of FK506-Binding Proteins
Circulation, April 28, 2009; 119(16): 2179 - 2187.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Heart Circ. Physiol.Home page
L. Vinet, P. Rouet-Benzineb, X. Marniquet, N. Pellegrin, L. Mangin, L. Louedec, J.-L. Samuel, and J.-J. Mercadier
Chronic doxycycline exposure accelerates left ventricular hypertrophy and progression to heart failure in mice after thoracic aorta constriction
Am J Physiol Heart Circ Physiol, July 1, 2008; 295(1): H352 - H360.
[Abstract] [Full Text] [PDF]